"Developing countries that have large populations must be prepared in the face of the emergence of new diseases, therefore DCVMN prioritizes vaccine development, among others, of Pentavalent / Hexavalent Vaccines, Pneumococcal Conjugate, Rotavirus, Typhoid Conjugate, Human Papilloma, Measles / Rubella and Inactivated Polio Vaccines, he added.
"The Management of Bio Farma is proud of the re-election of Mahendra Suhardono as the president of DCVMN for a second period, and the firm election of a candidate from the vaccine manufacturing representatives of a wide range of countries, such as Brazil, China, India, South Africa.
* DCVMN Member Country Information: Argentina, Brazil, Cuba, Egypt, India, Indonesia, Iran, Mexico, People's Republic of China, Republic of Korea, Romania, South Africa, Thailand, Viet Nam, South Korea, Iran
* DCVMN 15th Annual General Meeting: http://www.dcvmn.org/event/dcvmn-15th-annual-general-meeting
Homma said DCVMN countries have committed to increasing their efforts to develop vaccines to prevent millions of deaths caused by infectious disease.
The newly-elected president of the DCVMN, Mahendra Suhardono of Bio Farma, expressed his optimism that the organization could be better and become stronger, especially under his leadership for the next two years.
Kim Bush of Bill and Melinda Gates Foundation said at a meeting at the DCVMN
on Thursday that his organization appreciates Bio Farma for hosting this prestigious conference.
On the 13th DCVMN annual general meeting, he said the members could take advatange of the meeting for sharing their experience and know how on the research and development of new vaccines.
In total, there are currently 37 vaccine-making manufacturers in the 14 DCVMN member countries.The objective of the Bali meeting is to increase the availability and improve the quality of vaccines produced in developing countries.
"Bio Farma produces 1.4 billion doses of oral Polio vaccine, the biggest in the world," DCVMN
President Akira Homma told a press conference, in Kuta, Bali, on Tuesday, held as part of opening program of 13th annual general meeting to last 31 Oct - 2 Nov, 2012.
He explained that the purpose of holding the DCVMN
meeting is to jointly combat the spread of infectious diseases that are endemic in many developing countries.
Bio Farma President Director Iskandar said on Tuesday that DCVMN
is a strategic alliance among developing countries' vaccine manufacturers.